Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma

Daclizumab in treatment of multiple sclerosis patients

“…In the case of viral meningitis, the fact that the case along with other contacts developed illnesses after swimming in the lake makes it less likely that Daclizumab was the cause of meningitis though it may have reduced the immune system of the patient making the manifestation more severe. Interestingly, one patient with a family history of psoriasis developed the disease while on Daclizumab although there are reports of Daclizumab being used in the treatment of psoriasis [6][7][8]. These findings emphasize the need for caution in using new therapies to treat patients with MS. Further results from the ongoing controlled trials are expected to shed more light on the efficacy and tolerability of these therapies.…”

Biologic Therapy for Psoriasis

“…[39,40] Daclizumab, a humanized monoclonal anti-CD25 antibody has been tried in recalcitrant psoriasis [41] and in HIV-associated psoriatic erythroderma. [42] SIDE EFFECTS OF BIOLOGICS [1,3,[43][44] Allergic reaction and antibody formation They are mostly seen with TNF-α blockers. Mild transient injection site reactions comprising of erythema, edema and bruising are noted with etanercept in 10-20% of cases.…”

Biologics in dermatology

“…Daclizumab is a humanized monoclonal anti CD 25 (αsubunit) antibody. 12 Indications: Chronic plaque Psoriasis, recalcitrant psoriasis and HIV-associated psoriatic erythroderma. 12 It has been withdrawn from markets in 2018 due to the high risk of encephalitis and meningoencephalitis.…”